Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.

Steven G DuBois Meaghan P Granger Susan GroshenDenice Tsao-WeiLingyun JiAnasheh ShamirianScarlett CzarneckiFariba GoodarzianRachel BerkovichHiroyuki ShimadaJudith G VillablancaKieuhoa T Vo Navin R PintoYael P MosseJohn M Maris Suzanne Shusterman Susan L Cohn Kelly C Goldsmith Brian D WeissGregory A YanikClare J TwistMeredith S Irwin Daphne A Haas-Kogan Julie R ParkAraz MarachelianKatherine K Matthay

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Vorinostat and MIBG is likely the arm with the highest true response rate, with manageable toxicity. Vincristine and irinotecan do not appear to improve the response rate to MIBG and are associated with increased toxicity.

Keyphrases

open label
oxidative stress
acute myeloid leukemia
placebo controlled
double blind
multiple myeloma
randomized controlled trial
histone deacetylase
study protocol
oxide nanoparticles